Compare Tango Therapeutics Inc. (TNGX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.86 (market cap $17.73B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 4.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| TNGX | USIG | |
|---|---|---|
Market Cap | $3.74B | $17.73B |
Volume | 3,438,781 | 2,036,622 |
Sector | Health | Fixed Income |
52-Week High | $32.90 | $52.69 |
52-Week Low | $7.50 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The ETF maintains regular dividend distributions, with recent payments of $0.20-0.21 per share.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in its credit quality. Key risks include bond market volatility and credit spread fluctuations. Current technical weakness warrants caution despite the neutral sentiment from oscillators and institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
